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Abstract 
 
Perforin, a pore-forming toxin released from secretory granules of NK cells and 
CTLs, is essential for their cytotoxic activity against infected or cancerous target 
cells. Bi-allelic loss-of-function mutations in the perforin gene are invariably 
associated with a fatal immunoregulatory disorder, familial haemophagocytic 
lymphohistiocytosis type 2 (FHL2), in infants. More recently, it has also been 
recognized that partial loss of perforin function can cause disease in later life, 
including delayed onset FHL2 and haematological malignancies. Herein we 
report a family in which a wide range of systemic inflammatory and neoplastic 
manifestations have occurred across three generations. We found that disease 
was linked to two missense perforin gene mutations (encoding A91V, R410W) 
that cause protein misfolding and partial loss of activity. These cases link the 
partial loss of perforin function with some solid tumours that are known to be 
controlled by the immune system, as well as haematological cancers. Our 
findings also demonstrate that perforin gene mutations can contribute to 
hereditary cancer predisposition. 
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Introduction 
 
Perforin (PRF, encoded by the PRF1 gene) is a pore-forming toxin1 stored 
in the secretory granules of cytotoxic lymphocytes. During an immune response, 
these ‘killer’ cells form an immune synapse with a virus-infected or cancer target 
cell, and release PRF and granzyme serine proteases into the synaptic cleft.2 PRF 
forms membrane pores that are essential for cytotoxic lymphocyte pro-apoptotic 
serine proteases, granzymes, to enter the target cell cytoplasm, where they 
trigger apoptosis.3 
Bi-allelic mutations in PRF1 that completely abrogate function are 
classically associated with the paediatric immunoregulatory disorder familial 
haemophagocytic lymphohistiocytosis type 2 (FHL2),4 which accounts for 30-
60% of all FHL cases.5 However, it is possible that FHL2 represents one extreme 
of a spectrum of diseases caused by PRF deficiency.6 Thus, missense mutations 
causing partial loss of expression or function of PRF are more often associated 
with later atypical onset FHL27 and/or haematological malignancy.8-12 It is 
unknown whether PRF deficiency can predispose to solid tumours, nor has a 
possible contribution of PRF1 mutations to familial cancer ever been explored.  
Herein, we describe a UK family of Italian origin, in which adult onset 
FHL2, haematological and various solid tumours have affected three generations. 
We show that these diseases are consistently associated with PRF1 missense 
mutations, with defective protein folding causing partial loss of PRF expression. 
These findings highlight a novel hereditary cancer predisposition syndrome 
associated with PRF1 mutations. 
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Methods 
 
DNA sequencing 
Oligonucleotide primers used for PRF1 sequencing are available on request. 
 
PRF expression 
PBMNCs were surface stained using anti-CD56-PE, CD4-PerCP, CD8-APC, then 
fixed, permeabilized, and stained with cytofix/cytoperm and anti–human PRF-
FITC or isotype control (BD Biosciences). 100,000 lymphocytes were acquired on 
FACs Calibur and analysed by sequential gating using CellQuest Pro (BD 
Biosciences). 
 
Assessment of R410W function 
Primary murine Prf1-/- CD8+ T cells transgenic for the OT1 TCR were transiently 
transfected with either WT or mutant R410W PRF cDNA, as described 
previously.11,13 Cells were then used in four-hour 51Cr release assays against 
OVA257 (SIINFEKL peptide) labelled EL-4 thymoma target cells.11,13 % specific 
51Cr release was estimated as described.11 
 
Study approval 
All clinical investigation was conducted according to Declaration of Helsinki 
principles. All participants gave full informed consent for analysis of PRF 
expression and PRF1 mutation screening, and for the results to be reported in 
this study.  
 6 
Results and discussion 
 
A family pedigree showing members in whom PRF1 was analysed is 
shown in Figure 1. Further details, including PRF1 mutational analysis and NK 
cell PRF expression are summarised in Table 1.  
The index case, a 43 year-old woman (II-1), presented with lethargy, 
pyrexia and moderate splenomegaly. She was found to have pancytopenia, 
hyperferritinaemia, hypertriglyceridaemia and extensive haemophagocytosis in 
her bone marrow, leading to a diagnosis of HLH, based on the HLH-2004 
diagnostic criteria. Despite extensive investigation, no acquired cause for HLH 
could be found; rather,  the diagnosis of late onset FHL2 was supported by 
mutations in PRF1 and reduced intracellular PRF expression (Figure 2). 
Treatment was according to the HLH-1994 protocol, but the patient developed 
progressive multi-organ failure and died. 
Subsequently, two family members also carrying PRF1 mutations and 
with reduced intracellular PRF presented with de novo leukaemia. The index 
case’s niece (III-1) was diagnosed with acute lymphoblastic leukaemia (ALL), 
and her uncle (I-3) with chronic myelomonocytic leukaemia (CMML), which 
subsequently transformed to acute myeloid leukaemia (AML) (Table 1). A link 
between PRF1 mutations and lymphoid malignancies has been reported,8,10,11 
but to our knowledge this is the first case of CMML in association with PRF 
deficiency. 
Further investigation of the family’s medical history revealed that the 
father of the index case (I-1), who carried the same mutations as his daughter (II-
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1), had developed multiple primary malignancies as an adult, including renal cell 
carcinoma at 54 years of age, but had never been affected by HLH (Table 1). No 
other predisposing environmental or genetic cancer risk had been identified. A 
brother of the index case (II-2) developed intracranial glioma, which was rapidly 
fatal despite radiation therapy. Genotyping was not performed, but it could be 
deduced from his parents’ genotype that he would have carried at least one PRF1 
mutation, with a 50% probability of two mutations. To our knowledge, this is the 
first report of an association between human PRF1 mutations and solid tumours, 
some of which have previously been described to be under the control of the 
immune system.14,15  
The A91V allele identified in this family is by far the commonest 
hypomorphic PRF1 variant, being found in ~8% of Caucasians.5 A91V adversely 
affects PRF folding and this is typically thought to markedly reduce PRF levels 
and the cytotoxicity of CTL/NK cells.16,17 Although misfolded A91V PRF is 
detectable by standard methodologies  in healthy A91V heterozygotes,17 earlier 
reports suggested that A91V homozygote patients (or those who co-inherited 
A91V together with a null mutation) have severely reduced or absent PRF 
levels.16,18 In analysing patient II-3, who had bi-allelic A91V mutations but has 
remained healthy, we demonstrated, for the first time, that A91V homozygosity 
is indeed compatible with reduced, but still detectable PRF levels (Figure 2).  
This discrepancy may be related to PRF levels being assessed at times when a 
patient is extremely ill.  
In contrast, the R410W mutation, that also affects this family, has not 
been previously investigated. We found that R410W causes near-total loss of 
function, as the activity of Prf1-/- mouse CTLs transfected with the mutant was 
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<5% of the CTLs reconstituted with wild-type PRF (Figure 3A). As with other 
cancer-associated PRF1 mutations,11 when R410W-transfected T cells were 
cultured at reduced temperature (30˚C), their activity was restored to wild-type 
level (Figure 3B). The fact that the loss of activity of R410W is temperature-
dependent strongly suggests that protein misfolding is responsible for its 
functional impairment.11 
A91V and R410W both lead to PRF misfolding, which reduces but does 
not abolish PRF activity. Such in vitro studies on PRF mutants have previously 
been shown to be strong predictors of their behaviour in vivo in carriers of these 
mutations.11,17 Whereas the complete loss of PRF function typically presents in 
early childhood as FHL2, the subtotal loss of PRF activity causes systemic 
inflammatory disease that is delayed beyond infancy (as in the index case II-1) or 
may present as a different immunopathology.6 In these instances, consistent with 
Burnet’s hypothesis of tumour immune surveillance,19 reduced cytotoxic 
lymphocyte activity caused by partial loss of PRF may be expected to predispose 
to neoplasia, and this is indeed supported by previous studies.9-12 It is not clear, 
however, why these malignancies thus far reported in humans in association 
with PRF deficiency are predominantly haematological. It is possible that PRF 
defects lead to a reactive proliferation of the lymphoid and histiocytic pools, as 
typically observed in FHL, causing genomic instability and a predisposition to 
neoplasia in one of these lineages. Alternatively, haematological malignancies 
may be more susceptible to immune control than solid tumours and may thus 
arise more frequently in the absence of a fully functional immune system. This 
report supports the strong link between partial PRF deficiency and 
haematological malignancy. Critically, it also shows for the first time that 
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multiple solid tumours, some known to be controlled by immune system,14,15 can 
occur in humans in this context, thus validating earlier investigations in murine 
models, where many types of solid tumour, including prostate, mammary and 
lung carcinoma, were controlled by PRF-dependent cytotoxicity.20,21 Overall, in 
the current study, the penetrance of PRF1 mutations was over 50% with 5 out of 
9 carriers affected by disease (Table 1). Excluding patient II-2 (where genetic 
analysis was not performed), a similar penetrance was observed in both carriers 
of mono-allelic PRF1 mutations (2 out of 4 carriers affected) and family members 
with bi-allelic mutations (2 out of 4 carriers affected). 
Of particular note, the cases discussed in this report involve many family 
members and several generations. This is highly suggestive of a hereditary 
cancer predisposition syndrome,22 and we believe this is the first association of 
PRF1 mutations with such a disorder. Such findings align closely with a recent 
report highlighting increased incidence of cancer in relatives of patients with 
FHL.23 
Although hereditary cancer syndromes are typically autosomal dominant 
with incomplete penetrance, the pattern of inheritance is less clear in this family, 
with both mono-allelic and bi-allelic carriers of PRF1 mutations developing 
disease. One explanation for this variable pattern in inheritance is that PRF 
mutants such as A91V have been previously shown to exhibit dominant negative 
activity,17,24 and thus may cause pathology when only present on one allele. 
Furthermore, although PRF1 mutations may be acting alone, it is possible that 
another undetected mutation may be present in this family. For example, it has 
recently been shown that patients with FHL may co-inherit mutations in two 
different genes regulating lymphocyte cytotoxicity, although this is a rare event 
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leading to FHL mostly at a younger age.25 Besides, in the context of the family 
described here, co-inheritance of three pathological mutations would be 
required, with one leading to defective perforin secretion (UNC13D or STX11 or 
STXBP2). While this is theoretically possible, the probability of such an event is 
exceedingly small. Alternatively, PRF deficiency may be acting in concert with 
classical cancer predisposition genes unrelated to cytotoxic lymphocyte function. 
The latter possibility potentially opens up a new paradigm, which we believe 
warrants further investigation: that deficiency of an extrinsic tumour suppressor 
such as PRF may co-operate with an intrinsic genetic defect to predispose to 
familial cancer syndromes. 
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Figure and Table Legends 
 
Figure 1. Characterization of PRF1 defects within the family. Family 
pedigree showing the relationship between family members in which PRF1 
analysis was performed. An arrow indicates the index case. Each family 
member’s cancer history is also indicated (H=haematological malignancy; 
S=solid cancer; DF=disease free; U= unknown cancer history). 
 
Figure 2. Intracellular PRF expression in selected family members. 
Intracellular PRF expression in CD56+CD8- NK cells in patients I-1, II-3, II-5 and 
II-6 (serving as WT perforin control); in parenthesis is the median fluorescence 
intensity. Of note, patient II-3, who is homozygous for the A91V mutation but has 
remained healthy, demonstrates reduced, but appreciable PRF levels. 
 
Figure 3. Determining the nature of the R410W mutation. (A) At 37˚C, 
reconstitution of Prf1-/- CTLs with R410W mutant PRF leads to cytolytic activity 
(assessed by 51Cr release assays) <5% of Prf1-/- CTLs reconstituted with wild-
type perforin. (B) At 30˚C (a permissive temperature for protein folding) 11, Prf1-
/- CTLs transfected with R410W mutant PRF have cytolytic activity that is 
indistinguishable from Prf1-/- CTLs transfected with wild-type PRF. A complete 
recovery of R410W activity indicates that the only reason for its marginal 
activity at 37˚C is a severe misfolding, and the mutation itself does not affect PRF 
function.  
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Table 1: Summary of PRF defects and associated disease in family 
members. Analysis of PRF included PRF1 genotype (assessed by Sanger 
sequencing) and PRF expression in NK cells (assessed by intracellular FACS).  
The penetrance of PRF mutations was found to be over 50% with 5 out of 9 
carriers affected by disease, including solid tumours. 
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Figures and Tables 
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